ADOCIA Reinforces Its Board of Directors with the Appointment of Three New Independent Members
Regulatory News: ADOCIA (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides, announces
New York United States France General Columbia University Haute Normandie Pramlintide Biochaperone Lispro
Source: finanznachrichten.de